CJC-1295

What is CJC-1295?

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) and a growth hormone secretagogue (GHS) that was developed in the mid-2000s by ConjuChem Technologies. Originally designed to treat obesity issues in HIV/AIDS patients, the peptide has since been shown to effectively treat growth hormone deficiency, improve sleep quality, and promote longevity, and is classified as a prohibited substance under Section S2 of the World Anti-Doping Agency’s (WADA) Prohibited List

While standard CJC-1295 peptide is made up of 29 amino acids, it is most commonly available as CJC-1295 DAC, which stands for “Drug Affinity Complex.” DAC is a bioconjugation platform that improves the ability of the CJC-1295 peptide to bond with blood protein, giving it a much longer half-life than regular CJC-1295

What Does CJC-1295 Do?

CJC-1295 binds to receptors in the pituitary gland to stimulate the release of growth hormones plasma growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Its mechanism of action is similar to Sermorelin in that it raises GH levels and acts on the GHRH receptor. However, CJC-1295 takes longer than Sermorelin to clear from the body and exhibits longer periods of high GH, whereas Sermorelin creates a more natural release of GH.

The half-life of CJC-1295, which selectively binds to endogenous albumin, is extended considerably by the addition of DAC. CJC-1295 No DAC has a half-life of just thirty minutes, while CJC-1295 DAC has an estimated half-life of 6 to 10 days.

CJC-1295 Benefits | Clinical Trials

 CJC-1295 may promote deep sleep: Several studies have suggested that GHRH plays a direct role in improving the quality of sleep. As CJC-1295 is a synthetic analogue of GHRH, there is strong research interest in the role it may play in sleep.

 CJC-1295 may increase muscle mass: CJC-1295’s documented ability to increase levels of GH and IGF-1 has prompted research interest in the role that it may play in increasing muscle mass. CJC-1295 stimulates protein synthesis and supports muscle mass growth. While research in this area is ongoing, it remains to be determined whether healthy subjects may receive anabolic benefit from increased GH and IGF-1.

Researchers interested in exploring CJC-1295’s purported effect on muscle mass may consider a blend of CJC1295 & Ipamorelin. This peptide combination has been linked to increased protein synthesis and muscle mass growth.

 CJC-1295 may stimulate fat loss: Studies have shown that prolactin promotes visceral fat accrual in various animal models and that CJC-1295 can normalize prolactin levels as shown in GHRH knockout mice, which can lead to increased fat metabolization. These findings have led to strong research interest in the role that CJC-1295 may play in fat loss through prolactin regulation.

CJC-1295 with DAC Dosage

After measuring the peak concentrations and area under the curve of GH and IGF-1, researchers found that CJC-1295 increased mean plasma GH concentrations by 2- to 10-fold for 6 days or more, and increased mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 days.

Studies suggest that CJC-1295 boosts GH and IGF-I levels in healthy adults and is tolerated in a dose range of 30-60 μg/kg

1mg - 2mg weekly is a well tolerated over 12 weeks.